- Q1 2024 Organon & Co Earnings Call TranscriptMay 02, 2024$18.52Earnings
- Q4 2023 Organon & Co Earnings Call TranscriptFeb 15, 2024$18.52 (+13.89%)Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2023
- Q3 2023 Organon & Co Earnings Call TranscriptNov 02, 2023$12.89 (-11.80%)Earnings
- Q2 2023 Organon & Co Earnings Call TranscriptAug 08, 2023$23.81 (+8.44%)Earnings
- Q1 2023 Organon & Co Earnings Call TranscriptMay 04, 2023$22.22 (-8.22%)Earnings
- Q4 2022 Organon & Co Earnings Call TranscriptFeb 16, 2023$25.35 (-14.15%)Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Q3 2022 Organon & Co Earnings Call TranscriptNov 03, 2022$26.34 (+0.90%)Earnings
- Q2 2022 Organon & Co Earnings Call TranscriptAug 04, 2022$32.48 (-0.18%)Earnings
- Q1 2022 Organon & Co Earnings Call TranscriptMay 05, 2022$34.7 (+5.57%)Earnings
- Organon & Co at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Organon & Co Earnings Call TranscriptFeb 17, 2022$36.35 (+0.58%)Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2022
- Organon & Co at Evercore ISI HealthCONx Virtual Conference TranscriptDec 01, 2021
- Q3 2021 Organon & Co Earnings Call TranscriptNov 11, 2021$35.01 (-4.73%)Earnings
- Organon & Co at Morgan Stanley Global Healthcare Conference (Fireside Chat) TranscriptSep 13, 2021
- Q2 2021 Organon & Co Earnings Call TranscriptAug 12, 2021$33.63 (+11.67%)Earnings
Organon & Co at Cowen Health Care Conference (Virtual) Transcript
Good morning, and welcome to the Organon session of Cowen's 42nd Annual Healthcare Conference. We're very pleased to have with us the top management of Organon, one of the most unique and exciting and emerging companies in the biopharma space. So we're very pleased to have you with us at our conference.
Representing the company is Kevin Ali, who is the CEO; Matthew Walsh, who is the CFO; Sandra Milligan, who is the Head of R&D; and Jen Halchak, who is the Head of Investor Relations.
Questions & Answers
So with that, I'd like just to dive right into the Q&A. We'll centermost of the companies on the women's health area -- most of the questions on the women's health area, but we may sprinkle in a few others as well.
So let's start out with your most important product, that being NEXPLANON. Q4 for NEXPLANON was the highest quarter
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)